Clinical Trial Update: Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating treatment tailored to RAP80 and BRCA1 in advanced non-small cell lung cancer with BRCA1 mutation; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Spanish Lung Cancer Group | Conditions: Non Small Cell Lung Cancer, BRCA1 Mutation | Phase 3 | Status: TERMINATED | Results posted: 2024-01-30